Home Cart Sign in  
Chemical Structure| 1401682-78-7 Chemical Structure| 1401682-78-7

Structure of Senaparib
CAS No.: 1401682-78-7

Chemical Structure| 1401682-78-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Senaparib, also known as IMP4297, is s a novel highly potent and selective oral PARP1/2 inhibitor with strong antitumor activity in preclinical studies. Senaparib demonstrated encouraging clinical benefit and a favorable tolerability profile in patients with advanced solid tumour.

Synonyms: IMP4297; JS109

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Senaparib

CAS No. :1401682-78-7
Formula : C24H20F2N6O3
M.W : 478.45
SMILES Code : O=C(N1)N(CC2=CC=C(F)C(C(N3CCN(C4=NC=CC=N4)CC3)=O)=C2)C5=C(C(F)=CC=C5)C1=O
Synonyms :
IMP4297; JS109
MDL No. :MFCD32878274

Safety of Senaparib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Senaparib

epigenetics
DNA

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04351165 Solid Tumor PHASE1 COMPLETED 2021-04-30 Syneos Health, Sydney, Austral... More >>ia Less <<
NCT04089189 Ovarian Cancer PHASE2 UNKNOWN 2025-08-22 Xiaohua.Wu, Shanghai, China
NCT03507543 Advanced Solid Tumours|Breast ... More >>Cancer|Ovarian Cancer|Prostate Cancer|Primary Peritoneal Cancer Less << PHASE1 COMPLETED 2021-03-17 Blacktown Hospital, Blacktown,... More >> New South Wales, 2148, Australia|St George Private Hospital, Kogarah, New South Wales, Australia|Nucleus Network, Melbourne, Victoria, 3004, Australia Less <<
NCT03508011 Advanced Solid Tumours|Breast ... More >>Cancer|Ovarian Cancer|Prostate Cancer Less << PHASE1 COMPLETED 2020-12-16 Cancer Hospital Chinese Academ... More >>y of Medical Sciences, Beijing, Beijing, 100021, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200032, China Less <<
NCT04057729 Solid Tumor PHASE1 COMPLETED 2019-09-27 Shanghai Public Health Clinica... More >>l Center, Shanghai, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.09mL

0.42mL

0.21mL

10.45mL

2.09mL

1.05mL

20.90mL

4.18mL

2.09mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories